Delving into the Latest Updates on CG-BM1 Allogenic Bone marrow derived MSC (Guangzhou Cellgenes) with Synapse

Overview

Basic Info

Drug Type

Cell therapy

Synonyms

CG-BM1 Allogenic Human Bone Marrow Mesenchymal Stem Cell (Guangzhou Cellgenes)

Target-

Action-

Mechanism-

Therapeutic Areas

Digestive System DisordersRespiratory DiseasesOther Diseases+ [2]

Active Indication

Ischemic strokeAcute-On-Chronic Liver FailureRespiratory Distress Syndrome, Adult

Inactive Indication-

Originator Organization

Guangzhou Saijun Biotechnology Co., Ltd.

Active Organization

Guangzhou Saijun Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Primary purpose: To evaluate the safety and tolerability of CG-BM1 in the treatment of adult ACLF patients and determine the safety range of clinical medication. Secondary purpose: To observe the preliminary efficacy of CG-BM1 in the treatment of adult ACLF patients and provide a basis for the design of subsequent clinical trial programs.

Start Date24 Mar 2023

Sponsor / Collaborator

Guangzhou Saijun Biotechnology Co., Ltd.

NCT06740149

/ RecruitingPhase 1/2IIT

Efficacy and Safety of Allogeneic Human Bone Marrow Mesenchymal Stem Cells for the Treatment of Patients with Acute-on-chronic Liver Failure

The goal of this clinical trial is to learn if CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection (hereinafter referred to as CG-BM1) can treat acute-on-chronic liver failure (ACLF) patients. Main purposes of this clinical trial are:
* To evaluate the safety and tolerability of CG-BM1 for the treatment of adult patients with ACLF.
* To observe the preliminary effectiveness of CG-BM1 in treating adult ACLF patients, and to provide a basis for subsequent clinical trial protocol design.

Start Date01 Mar 2023

Sponsor / Collaborator

Sun Yat-Sen University

[+1]

100 Clinical Results associated with CG-BM1 Allogenic Bone marrow derived MSC (Guangzhou Cellgenes)

Login to view more data

100 Translational Medicine associated with CG-BM1 Allogenic Bone marrow derived MSC (Guangzhou Cellgenes)

Login to view more data

100 Patents (Medical) associated with CG-BM1 Allogenic Bone marrow derived MSC (Guangzhou Cellgenes)

Login to view more data

100 Deals associated with CG-BM1 Allogenic Bone marrow derived MSC (Guangzhou Cellgenes)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ischemic stroke	Phase 2	China	Guangzhou Saijun Biotechnology Co., Ltd.	31 Jul 2025
Acute-On-Chronic Liver Failure	Phase 2	China	Guangzhou Saijun Biotechnology Co., Ltd.	20 Aug 2024
Respiratory Distress Syndrome, Adult	Phase 1	China	Guangzhou Saijun Biotechnology Co., Ltd.	04 Jan 2023